MIPT Experimental Chemical Production Workshop

History

2025: Launch of "SHOP"

On the territory of the Moscow Institute of Physics and Technology (MIPT), a "WORKSHOP" of experimental chemical production was launched. This site was created for the complete development and scaling of technologies for the synthesis of active pharmaceutical substances (APIs) - both for generic and for drugs. The workshop will strengthen Russia's position in the field of import substitution policy and will become an assembly point for collaborations between science and industry. MIPT announced this on August 26, 2025.

The opening of the workshop is the basis of the future, where collaborations between several pharmaceutical companies and scientific groups of MIPT will allow launching full-fledged projects to create domestic innovative drugs. The appearance of such a cluster at the university is a natural response to the requests of the developing domestic pharmaceutical industry. The main prerequisite is the growing need of pharmaceutical companies to localize the production of active substances on the territory of the Russian Federation, caused by the state policy of import substitution and the desire of manufacturers to get competitive advantages on the market.

The launch of the experimental chemical workshop is not just the commissioning of a new site, but a powerful impetus for the development of all domestic pharmaceuticals. We are creating an ecosystem where the scientific development of our laboratories will quickly reach real production, providing the country with its own, competitive substances and innovative drugs. We see a keen interest on the part of pharmaceutical companies in high-quality, "unreasonable" technologies, and are ready to respond to it, acting as a reliable scientific and production partner, "said Dmitry Livanov, rector of MIPT.

According to the founders, there are several main goals for creating a cluster. Firstly, this is the scaling of technologies: the translation of laboratory developments into ready-made, described and reproducible industrial technologies that can be immediately implemented at partner factories.

The ability to scale technology increases our appeal as a performer: from a small flask to a large reactor, we can develop technology and give a partner a ready-made solution. Also among the goals is to stimulate innovation - providing an infrastructure base for the development of original full-cycle drugs - from computer design of the molecule to preclinical research. In addition, there are tasks for the production of niche products. The ideal scenario is if we find popular products, raw materials necessary for pharmaceutical companies, which will be economically feasible for us to produce. Thus, "WORKSHOP" is our step from providing services to producing our own goods, "said Anton Alasheev, head of the laboratory for preclinical research at MIPT.

The key feature of SHOP is the ability to carry out turnkey work: from the synthesis of milligrams of a new compound in the laboratory to the development of the technology for its production in industrial reactors with a volume of up to 100 liters. The cluster infrastructure includes a line of chemical reactors (10, 20, 50, 100 L), industrial centrifuges and other equipment for scaling processes.

This solves a critical task for the industry, reducing the time and costs of pharmaceutical companies to start production and reducing their dependence on foreign suppliers of raw materials.

"SHOP" opens a stage in the development of MIPT as a center of biomedical technologies. The site becomes a hub for collaborations between commercial customers and scientific laboratories of the institute. Already in August 2025, joint projects are underway with the laboratory of computer design of drugs and the laboratory of structural and functional research of innovative anticancer agents of the Moscow Institute of Physics and Technology under the leadership of Philip Maksimov.

{{quote 'The appearance of its experimental production is a good opportunity for scientists and future MIPT specialists to touch the devices that work at existing plants. On the one hand, in the context of a changing global situation and sanctions policy, we must take much larger steps towards practical industry and meet the needs of production. On the other hand, we must not forget about innovation. Our drugs, which will be required in a number of years - not so long, in 5, 7, 10 years - must be created now. And such sites bring us closer to these goals, - commented Roman Ivanov, Director of Innovation Development at Pharmasintez JSC. }}